Neumora Therapeutics IPO Presentation Deck

NMRA-266: Potentially Differentiated M4R PAM for Schizophrenia Pharmacology Designed as a highly selective positive allosteric modulator (PAM) for the M4 muscarinic receptor for antipsychotic-like efficacy with the potential for improved safety profile with an oral once-daily dosing profile Indication Schizophrenia Epidemiology Estimated 3 million patients in the U.S. with schizophrenia¹ Status Plan to submit IND to FDA in 4Q 2023 Drug Profile Oral, once-daily Strong IP Protection Expect exclusivity through 2042+, based on composition of matter protection and estimated patent term extension 1) Wander, C. Am J Manag Care. 2020;26:S62-S68. Emerging Clinical Activity Muscarinic receptor-targeting compounds have demonstrated potential as an approach to treating schizophrenia Endogenous pathways Enhanced in disease Drug impact Pre-synaptic neuron Synaptic cleft STRIATAL DOPAMINE HYPERACTIVITY Dopaminet receptor In SZ, hyperactivity of striatal dopamine and cortical glutamate contribute to disease pathology O- Dopamine Neurotransmitter Overactive dopamine pathways ACh DA M4R Glu NMRA-M4R Positive allosteric modulator of the M4 muscarinic receptor CORTICOSTRIATAL GLUTAMATE HYPERACTIVITY Glutamate-O Glutamatergic receptor Overactive glutamate pathways Confidential 19

View entire presentation